Eißmann, M.* ; Melzer, I.M.* ; Fernández, S.B.* ; Michel, G. ; Hrabě de Angelis, M. ; Hoefler, G.* ; Finkenwirth, P.* ; Jauch, A.* ; Schoell, B.* ; Grez, M.* ; Schmidt, M.* ; Bartholomae, C.C.* ; Newrzela, S.* ; Haetscher, N.* ; Rieger, M.* ; Zachskorn, C.* ; Mittelbronn, M.* ; Zörnig, M.*
Overexpression of the anti-apoptotic protein AVEN contributes to increased malignancy in hematopoietic neoplasms.
Oncogene 32, 2586–2591 (2013)
AVEN has been identified as an inhibitor of apoptosis, which binds to the adaptor protein, APAF-1, and thereby prevents apoptosome formation and mitochondrial apoptosis. Recent data have demonstrated high expression levels of AVEN messenger RNA in acute leukemias as well as a positive correlation between AVEN mRNA overexpression and poor prognosis in childhood acute lymphoblastic leukemia. On the basis of these data, we investigated the potential involvement of AVEN in tumorigenesis. First, we confirmed the overexpression of AVEN in T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) patient samples. We then established a transgenic mouse model with T-cell-specific overexpression of AVEN, with which we demonstrated the oncogenic cooperation of AVEN with heterozygous loss of p53. Finally, we used a subcutaneous xenograft mouse model to show that AVEN knockdown in the T-ALL cell lines, MOLT-4 and CCRF-CEM, and in the acute myeloblastic leukemia cell line, Kasumi-1, leads to a halt in tumor growth owing to the increased apoptosis and decreased proliferation of tumor cells. Collectively, our data demonstrate that the anti-apoptotic molecule, AVEN, functions as an oncoprotein in hematopoietic neoplasms.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publication type
Article: Journal article
Document type
Scientific Article
Thesis type
Editors
Keywords
AVEN; apoptosis; T-ALL; acute lymphoblastic leukemia; p53; transgenic mice; Acute Lymphoblastic-leukemia ; Cancer-cells ; Apoptosome ; Activation ; Hallmarks ; Tumors ; Mouse ; Mice
Keywords plus
Language
english
Publication Year
2013
Prepublished in Year
2012
HGF-reported in Year
2012
ISSN (print) / ISBN
0950-9232
e-ISSN
0950-9232
ISBN
Book Volume Title
Conference Title
Conference Date
Conference Location
Proceedings Title
Quellenangaben
Volume: 32,
Issue: 20,
Pages: 2586–2591
Article Number: ,
Supplement: ,
Series
Publisher
Nature Publishing Group
Publishing Place
Day of Oral Examination
0000-00-00
Advisor
Referee
Examiner
Topic
University
University place
Faculty
Publication date
0000-00-00
Application date
0000-00-00
Patent owner
Further owners
Application country
Patent priority
Reviewing status
Peer reviewed
POF-Topic(s)
30201 - Metabolic Health
Research field(s)
Genetics and Epidemiology
PSP Element(s)
G-500600-003
G-500600-001
Grants
Copyright
Erfassungsdatum
2012-08-20